{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Essential+Amino+Acid%2B&page=2",
    "query": {
      "intervention": "Essential Amino Acid+",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 340,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Essential+Amino+Acid%2B&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Essential+Amino+Acid%2B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T01:03:53.923Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01155609",
      "title": "L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mucositis",
        "Oral Complications of Chemotherapy",
        "Oral Complications of Radiation Therapy",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage I Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage I Basal Cell Carcinoma of the Lip",
        "Stage I Lymphoepithelioma of the Nasopharynx",
        "Stage I Lymphoepithelioma of the Oropharynx",
        "Stage I Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage I Salivary Gland Cancer",
        "Stage I Squamous Cell Carcinoma of the Hypopharynx",
        "Stage I Squamous Cell Carcinoma of the Larynx",
        "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage I Squamous Cell Carcinoma of the Nasopharynx",
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage I Verrucous Carcinoma of the Larynx",
        "Stage I Verrucous Carcinoma of the Oral Cavity",
        "Stage II Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage II Basal Cell Carcinoma of the Lip",
        "Stage II Lymphoepithelioma of the Nasopharynx",
        "Stage II Lymphoepithelioma of the Oropharynx",
        "Stage II Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage II Salivary Gland Cancer",
        "Stage II Squamous Cell Carcinoma of the Hypopharynx",
        "Stage II Squamous Cell Carcinoma of the Larynx",
        "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage II Squamous Cell Carcinoma of the Nasopharynx",
        "Stage II Squamous Cell Carcinoma of the Oropharynx",
        "Stage II Verrucous Carcinoma of the Larynx",
        "Stage II Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Lymphoepithelioma of the Oropharynx",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Basal Cell Carcinoma of the Lip",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Lymphoepithelioma of the Oropharynx",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Verrucous Carcinoma of the Larynx",
        "Stage IV Verrucous Carcinoma of the Oral Cavity"
      ],
      "interventions": [
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "L-lysine",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-05-17",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155609"
    },
    {
      "nct_id": "NCT04055428",
      "title": "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Cardiovascular Diseases",
        "Insulin Sensitivity/Resistance",
        "Metabolic Disease",
        "Natriuretic Peptides",
        "Metabolism",
        "Energy Expenditure"
      ],
      "interventions": [
        {
          "name": "Sacubitril, Valsartan 97-103 mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Standardized Meals",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise capacity VO2 maximum determination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-08-15",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055428"
    },
    {
      "nct_id": "NCT00076414",
      "title": "The Effect of Lopinavir/Ritonavir on Endothelial Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Acetylcholine",
          "type": "DRUG"
        },
        {
          "name": "L-NMMA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076414"
    },
    {
      "nct_id": "NCT03988634",
      "title": "Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction (HFpEF)"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "valsartan",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan matching placebo",
          "type": "DRUG"
        },
        {
          "name": "valsartan matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 467,
      "start_date": "2019-06-29",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 87,
      "location_summary": "Irvine, California • Long Beach, California • Los Angeles, California + 77 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988634"
    },
    {
      "nct_id": "NCT05705414",
      "title": "Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Valine",
          "type": "DRUG"
        },
        {
          "name": "EEA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 28,
      "start_date": "2024-10-18",
      "completion_date": "2026-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05705414"
    },
    {
      "nct_id": "NCT04314596",
      "title": "The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oxidative Stress",
        "Muscle Strength",
        "Resistance Training",
        "Body Composition",
        "Muscle Damage"
      ],
      "interventions": [
        {
          "name": "Cross Training Course",
          "type": "OTHER"
        },
        {
          "name": "Oceanix",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Applied Science & Performance Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-01-20",
      "completion_date": "2020-02-19",
      "has_results": false,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04314596"
    },
    {
      "nct_id": "NCT05078775",
      "title": "Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Locally Advanced Unresectable Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "NEAAR Medical Food",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Faeth Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2021-12-21",
      "completion_date": "2025-07-10",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Glendale, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05078775"
    },
    {
      "nct_id": "NCT01172301",
      "title": "Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Essential amino acid intake + Leucine vs total AA supplement",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 14,
      "start_date": "2008-07",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2015-08-11",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172301"
    },
    {
      "nct_id": "NCT03508739",
      "title": "Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Pre-diabetic",
        "Hypertension",
        "Elevated Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Sacubitril/Valsartan 200mg (blinded)",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160mg (blinded)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508739"
    },
    {
      "nct_id": "NCT05123365",
      "title": "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Neoplasm",
        "MPN",
        "Essential Thrombocythemia",
        "Polycythemia Vera",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2022-01-03",
      "completion_date": "2026-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-06T01:03:53.923Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Orange, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123365"
    }
  ]
}